Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2025-02-14
2028-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
NCT03571997
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
NCT06024694
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT01369784
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
NCT05162170
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
NCT06734078
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Plasmablastic lymphoma patients
Patients with diagnosis (histologically confirmed) of plasmablastic lymphoma (PBL) between Jan 1st 2000 and Dec 31st 2022
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
* Age \> 18 years old
* Availability of complete medical records
* Availability of histopathological material requested by the study
Exclusion Criteria
* Lack of complete medical records
* Lack of histopathological material requested by the study
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AIL Roma - Italia
UNKNOWN
AIL Cuneo - Italia
UNKNOWN
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessia Castellino, MD
Role: PRINCIPAL_INVESTIGATOR
UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy
Emanuele Ravano, MD
Role: PRINCIPAL_INVESTIGATOR
UO Ematologia, Niguarda Grande Ospedale Metropolitano, Milano - Italy.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati
Aviano, PN, Italy
Ospedale C.e G. Mazzoni, U.O.C. di Ematologia
Ascoli Piceno, , Italy
ASST Spedali Civili di Brescia, Ematologia
Brescia, , Italy
A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
Cuneo, , Italy
Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia
Florence, , Italy
ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia
Milan, , Italy
ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
Milan, , Italy
Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
Milan, , Italy
Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia
Milan, , Italy
Fondazione IRCCS San Gerardo dei Tintori, Ematologia
Monza, , Italy
AOU Maggiore della Caritа di Novara, SCDU Ematologia
Novara, , Italy
Azienda Ospedaliera Universitaria di Padova, Ematologia
Padua, , Italy
Presidio ospedaliero A. Tortora, U.O. Onco-ematologia
Pagani, , Italy
Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia
Reggio Emilia, , Italy
Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia
Roma, , Italy
Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione
Roma, , Italy
Universitа Cattolica S. Cuore, Ematologia
Roma, , Italy
Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia
Siena, , Italy
A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria
Torino, , Italy
A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia
Torino, , Italy
Ospedale S. Chiara, S.S. di Ematologia
Trento, , Italy
ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia
Treviso, , Italy
ULSS 8 Berica - Ospedale S. Bortolo, Ematologia
Vicenza, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIL_PlaLy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.